The stock of Applied Dna Sciences Inc (APDN) has gone up by 15.85% for the week, with a -72.99% drop in the past month and a -81.79% drop in the past quarter. The volatility ratio for the week is 21.39%, and the volatility levels for the past 30 days are 16.68% for APDN. The simple moving average for the past 20 days is -55.49% for APDN’s stock, with a -90.72% simple moving average for the past 200 days.
Is It Worth Investing in Applied Dna Sciences Inc (NASDAQ: APDN) Right Now?
APDN has 36-month beta value of 0.79. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for APDN is 1.03M, and currently, short sellers hold a 5.83% ratio of that float. The average trading volume of APDN on March 25, 2025 was 558.86K shares.
APDN) stock’s latest price update
Applied Dna Sciences Inc (NASDAQ: APDN)’s stock price has soared by 18.44 in relation to previous closing price of 1.79. Nevertheless, the company has seen a gain of 15.85% in its stock price over the last five trading days. accessnewswire.com reported 2025-03-12 that STONY BROOK, NY / ACCESS Newswire / March 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the “Company”), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-50 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m.
Analysts’ Opinion of APDN
Many brokerage firms have already submitted their reports for APDN stocks, with ROTH Capital repeating the rating for APDN by listing it as a “Buy.” The predicted price for APDN in the upcoming period, according to ROTH Capital is $24 based on the research report published on February 12, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see APDN reach a price target of $14, previously predicting the price at $18. The rating they have provided for APDN stocks is “Buy” according to the report published on January 14th, 2021.
H.C. Wainwright gave a rating of “Buy” to APDN, setting the target price at $12 in the report published on December 18th of the previous year.
APDN Trading at -70.68% from the 50-Day Moving Average
After a stumble in the market that brought APDN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.58% of loss for the given period.
Volatility was left at 16.68%, however, over the last 30 days, the volatility rate increased by 21.39%, as shares sank -72.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -78.51% lower at present.
During the last 5 trading sessions, APDN rose by +15.85%, which changed the moving average for the period of 200-days by -91.72% in comparison to the 20-day moving average, which settled at $4.7700. In addition, Applied Dna Sciences Inc saw -79.22% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for APDN
Current profitability levels for the company are sitting at:
- -3.53 for the present operating margin
- 0.34 for the gross margin
The net margin for Applied Dna Sciences Inc stands at -2.28. The total capital return value is set at -0.97. Equity return is now at value -100.40, with -65.89 for asset returns.
Based on Applied Dna Sciences Inc (APDN), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -21.87.
Currently, EBITDA for the company is -14.02 million with net debt to EBITDA at 0.68. When we switch over and look at the enterprise to sales, we see a ratio of -1.7. The receivables turnover for the company is 4.1for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.72.
Conclusion
To put it simply, Applied Dna Sciences Inc (APDN) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
